Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%

Follow CRL

Alert me

Market cap: $14.6B
P/E: 0.0×
Fwd P/E: 29.6×
Dividend yield: —
F-score: 5/9
Altman Z: 2.40
Beneish M: −3.11
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Impairment Feb 18, 2026

All filings →

Insider Decisions trades per month

Total buys 0.01

Total sells 42.91

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	1	—
Sell	—	—	—	—	—	—	—	1	—	9	—	1

Insider Ownership 1.71%

Capital & Financial Ratios $m

Market Cap 14,620.00

Revenue 3,998.99

Net Income (236.30)

Free Cash Flow 370.61

Net Debt 2,427.96

Current Ratio 1.35

Debt/Equity 0.92

P/E ratio 0.00

Fwd P/E 29.60

P/S ratio 3.60

P/B ratio 5.06

Past 5Y EPS Growth —

This Y EPS Growth 10.66%

Next Y EPS Growth 12.53%

Next Y revenue growth (2.43%)

Next 5Y EPS Growth 11.75%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 83.63%

10-year low 10-year high

P/B against its own 10 years 75.60%

10-year low 10-year high

EV/Sales against its own 10 years 83.27%

10-year low 10-year high

EV/FCF against its own 10 years 89.02%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	277	195	214	192
Receivables	780	721	709	712
Inventory	380	279	299	346
Other	83	106	129	179
	1,609	1,403	1,447	1,529

	2023	2024	2025	Q'26
Payables	169	140	149	141
ST’ Debt	—	—	—	—
Other	203	194	222	223
	1,055	994	1,120	1,135

Compound Annual Growth %

	10y	5y	3y
Sales	11.41%	6.55%	0.33%
Cash Flow	9.17%	6.18%	5.98%
Earnings	0.00%	0.00%	0.00%
Book Value	15.70%	8.40%	2.07%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	996	1,004	—	—	—
’25	984	1,032	1,005	994	4,015
’24	1,012	1,026	1,010	1,003	4,050
’23	1,029	1,060	1,027	1,013	4,129
’22	914	973	989	1,100	3,976
’21	825	915	896	905	3,540
’20	707	683	743	791	2,924

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	41	180	—	—	—
’25	172	205	214	148	738
’24	130	194	252	159	735
’23	109	148	205	221	684
’22	103	149	133	235	620
’21	170	187	175	229	761
’20	69	162	177	138	547

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	149	—	—	—
’25	112	169	178	59	518
’24	51	154	213	84	502
’23	3	81	140	143	365
’22	22	67	60	146	295
’21	142	140	119	130	532
’20	43	136	151	51	380

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.30)	(0.03)	—	—	—
’25	0.50	1.06	1.10	(5.62)	(2.91)
’24	1.30	1.74	1.33	(4.22)	0.20
’23	2.01	1.89	1.69	3.62	9.22
’22	1.81	2.13	1.88	3.65	9.48
’21	1.20	1.72	2.01	2.67	7.60
’20	1.02	1.34	2.03	2.81	7.20

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	65.70	75.25	96.70	103.00	95.58	243.37	181.36	161.65	176.48	91.86	Analyst estimates 2026–2028 Powerpack
	High	89.18	119.05	139.72	153.39	257.88	460.21	376.78	262.00	275.00	205.00
People
People	Employees	11,000	11,800	14,700	17,100	18,400	20,000	21,400	21,800	20,100	19,700
	Revenue/emp, $m	0.15	0.16	0.15	0.15	0.16	0.18	0.19	0.19	0.20	0.20
Income, $m
Income, $m	Revenue	1,681	1,858	2,266	2,621	2,924	3,540	3,976	4,129	4,050	4,015
	Gross margin, %	38.30	37.73	37.07	36.56	36.72	37.70	36.79	36.39	32.88	32.96
	EBT	223	297	282	304	447	481	623	581	93	(100)
	EBT margin, %	13.26	15.99	12.43	11.60	15.29	13.58	15.67	14.08	2.30	(2.48)
	Net income	156	125	229	254	365	399	493	480	25	(142)
	Depreciation	127	131	162	198	235	266	304	314	577	568
Per share, $
Per share, $	Revenue	35.76	39.12	47.26	53.79	59.01	70.39	78.25	80.61	78.82	81.01
	Earnings	3.29	2.60	4.72	5.17	7.35	7.77	9.57	9.27	0.20	(2.91)
	Cash flow	6.74	6.70	9.20	9.87	11.03	15.13	12.19	13.35	14.30	14.88
	Capex	(1.18)	(1.74)	(2.92)	(2.88)	(3.36)	(4.55)	(6.39)	(6.22)	(4.53)	(4.42)
	Free cash flow	5.56	4.96	6.28	6.99	7.67	10.58	5.80	7.13	9.76	10.46
	Book value	17.85	22.06	27.53	33.61	42.75	50.48	58.67	70.32	67.48	63.96
	Shares, m	47	47	48	49	50	50	51	51	51	50
Valuation, ×
Valuation, ×	P/E	23.19	42.72	24.08	29.55	34.04	48.49	22.82	25.30	1,025.56	0.00
	P/S	2.14	2.83	2.39	2.84	4.23	5.35	2.79	2.91	2.34	2.46
	P/B	4.29	5.02	4.11	4.55	5.84	7.46	3.72	3.33	2.74	3.12
	EV/Sales	2.80	3.36	3.04	3.47	4.83	6.05	3.41	3.48	2.85	2.94
	EV/FCF	18.02	26.46	22.91	26.71	37.19	40.24	46.02	39.34	22.99	22.78
Cash, $m
Cash, $m	Operating cash flow	317	318	441	481	547	761	620	684	735	738
	Capex	(55)	(82)	(140)	(141)	(167)	(229)	(325)	(319)	(233)	(219)
	Free cash flow	262	236	301	340	380	532	295	365	502	518
Balance, $m
Balance, $m	Working capital	227	363	340	311	361	241	347	554	409	327
	Total debt	1,235	1,145	1,668	1,888	1,980	2,664	2,708	2,647	2,240	2,136
	Net debt	1,117	981	1,473	1,650	1,751	2,422	2,474	2,370	2,046	1,923
	Shareholders’ equity	839	1,047	1,320	1,638	2,118	2,539	2,981	3,602	3,467	3,170
Returns, %
Returns, %	ROA	6.48	4.37	6.67	5.90	7.15	6.25	6.65	6.01	0.13	(1.97)
	ROIC	7.59	8.88	7.42	6.67	6.99	7.43	7.46	6.46	2.58	0.31
	ROE	19.63	13.08	19.13	17.04	19.40	16.79	17.62	14.42	0.29	(4.35)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DGX Quest Diagnostics Incorporated	$26.4B	24.6×	20.8×	+10.21% (above 0%: growing)	+14.74% (above 0%: growing)	+5.28% (above 0%: growing)	33.75%	15.08%	Compare
LH Labcorp Holdings Inc.	$26.4B	26.2×	19.0×	+5.78% (above 0%: growing)	+28.42% (above 0%: growing)	−42.01% (below 0%: shrinking)	29.80%	12.10%	Compare
GH Guardant Health, Inc.	$22.3B	— (loss-making)	— (loss-making)	+44.33% (above 0%: growing)	n/m	−5.46% (below 0%: shrinking)	65.39%	(38.55%)	Compare
MEDP Medpace Holdings, Inc.	$17.6B	35.6×	26.7×	+17.24% (above 0%: growing)	+36.39% (above 0%: growing)	−3.03% (below 0%: shrinking)	71.36%	20.76%	Compare
RVTY Revvity Inc.	$17.3B	72.7×	37.5×	+1.31% (above 0%: growing)	+2.17% (above 0%: growing)	+59.29% (above 0%: growing)	57.13%	12.24%	Compare
CRL Charles River Laboratories International, Inc.	$14.6B	— (loss-making)	29.6×	−2.72% (below 0%: shrinking)	n/m	−12.22% (below 0%: shrinking)	36.19%	11.94%
ICLR ICON PLC	$13.5B	254×	23.8×	+1.20% (above 0%: growing)	−59.31% (below 0%: shrinking)	+109.66% (above 0%: growing)	23.23%	6.68%	Compare
QGEN QIAGEN N.V.	$9.5B	23.6×	17.5×	+0.28% (above 0%: growing)	+7.94% (above 0%: growing)	+30.45% (above 0%: growing)	63.62%	24.75%	Compare
TWST Twist Bioscience Corporation	$9.5B	— (loss-making)	— (loss-making)	+23.24% (above 0%: growing)	n/m	−7.23% (below 0%: shrinking)	52.76%	(30.65%)	Compare
Median of peers	$17.4B	30.9×	22.3×	+8.00%	+11.34%	+1.13%	54.95%	12.17%

All 52 Diagnostics & Research stocks →

Charles River Laboratories International, Inc. (CRL) key facts

Concern: Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
Concern: Charles River Laboratories International, Inc. reported a net loss of $142.2 million, or a loss of $2.91 per share, for fiscal 2025.
Charles River Laboratories International, Inc. (CRL) is a Diagnostics & Research company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, CRL traded at $299.77, a market capitalization of $14.6 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 3.6× sales.
Return on equity was −4.35% and debt-to-equity 0.92.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 2.40 (grey zone) for fiscal 2025.